About us

The primary challenge is definition of what truly constitutes a rare gynaecological tumour. The GYNOCARE consortium has agreed to focus on the list of rare gynaecological cancers as adapted from the WHO classification of tumors Editoral Board: Female Genital Tumours., IARC 2020 (WHO classification of tumors series, 5th ed.; Volume 4)

The standardization of clinical and histopathological guidelines when defining a rare gynaecological tumour is of paramount relevance both for the diagnosis itself, and for designing clinical trials for testing new therapies. Therefore, for both translational studies and clinical trials, pathology input is crucial to determine the diagnosis, using appropriate diagnostic criteria, including immunohistochemistry and, where appropriate, molecular testing.

GYNOCARE will interact with different stakeholders and also train the current and next generation of early researchers, and professionals by organising training schools, workshops, conferences and short term scientific missions (STSMs),

The quality of research in rare gynaecological cancer will be improved through this COST Action by:

• advancing the state-of-the-art in the field of rare gynaecological cancer;
• developing new less- or non-invasive diagnostic methods for an earlier diagnosis, as well as improving treatment of rare gynaecological cancer;
• increasing the application of nanotechnology both in diagnosis and therapy; and
• developing prospective databases with biobanking.

Click here for more details.